A detailed history of Lazard Asset Management LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Lazard Asset Management LLC holds 2,763 shares of ITCI stock, worth $236,650. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,763
Previous 2,763 -0.0%
Holding current value
$236,650
Previous $189,000 6.88%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$64.76 - $79.84 $114,366 - $140,997
1,766 Added 177.13%
2,763 $189,000
Q3 2023

Nov 14, 2023

BUY
$52.09 - $64.1 $28,076 - $34,549
539 Added 117.69%
997 $51,000
Q2 2023

Aug 14, 2023

BUY
$54.67 - $66.44 $25,038 - $30,429
458 New
458 $29,000
Q4 2021

Feb 09, 2022

SELL
$35.2 - $53.42 $1.11 Million - $1.68 Million
-31,525 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$28.72 - $42.49 $905,398 - $1.34 Million
31,525 New
31,525 $1.18 Million

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $8.09B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Lazard Asset Management LLC Portfolio

Follow Lazard Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lazard Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lazard Asset Management LLC with notifications on news.